Technical Analysis for ARGX - argenx SE
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Overbought | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Crossed Above 50 DMA | Bullish | 1.48% | |
| MACD Bullish Centerline Cross | Bullish | 1.48% | |
| 180 Bullish Setup | Bullish Swing Setup | 1.48% | |
| Gapped Up | Strength | 1.48% | |
| Fell Below 50 DMA | Bearish | 6.56% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 6.56% | |
| 200 DMA Support | Bullish | 6.56% | |
| Outside Day | Range Expansion | 6.56% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 1% | about 19 hours ago |
| Bullish 180 Entry | about 19 hours ago |
| Rose Above Previous Day's High | about 19 hours ago |
| 2x Volume Pace | about 19 hours ago |
| 1.5x Volume Pace | about 19 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/05/2022
argenx SE Description
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Immunotherapy Autoimmune Disease Cancer Immunotherapy Inflammation Lymphoma Acute Myeloid Leukemia Rheumatoid Arthritis Lipid Myelodysplastic Syndrome Treatment Of Autoimmune Disease Dyslipidemia Hematological Cancers Myasthenia Myasthenia Gravis Thrombocytopenia Janus Kinase Inhibitor Skin Inflammation Treatment Of Hematological Cancers Rgx Tolerx
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 356.78 |
| 52 Week Low | 249.5 |
| Average Volume | 298,644 |
| 200-Day Moving Average | 304.58 |
| 50-Day Moving Average | 308.19 |
| 20-Day Moving Average | 301.91 |
| 10-Day Moving Average | 302.94 |
| Average True Range | 15.41 |
| RSI | 56.71 |
| ADX | 16.59 |
| +DI | 22.02 |
| -DI | 24.30 |
| Chandelier Exit (Long, 3 ATRs) | 280.78 |
| Chandelier Exit (Short, 3 ATRs) | 313.65 |
| Upper Bollinger Bands | 331.17 |
| Lower Bollinger Band | 272.64 |
| Percent B (%b) | 0.89 |
| BandWidth | 19.39 |
| MACD Line | 2.05 |
| MACD Signal Line | -0.99 |
| MACD Histogram | 3.04 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 339.74 | ||||
| Resistance 3 (R3) | 338.31 | 331.88 | 337.23 | ||
| Resistance 2 (R2) | 331.88 | 328.05 | 332.59 | 336.39 | |
| Resistance 1 (R1) | 328.28 | 325.68 | 330.08 | 329.71 | 335.56 |
| Pivot Point | 321.85 | 321.85 | 322.75 | 322.56 | 321.85 |
| Support 1 (S1) | 318.25 | 318.02 | 320.05 | 319.68 | 313.82 |
| Support 2 (S2) | 311.82 | 315.65 | 312.53 | 312.99 | |
| Support 3 (S3) | 308.22 | 311.82 | 312.15 | ||
| Support 4 (S4) | 309.65 |
